UNSPSC 51385001: Anirolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9B9E35WUX, chemically known as 1h-pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-(4-methoxybenzoyl)-, (+-)- but generally known as anirolac, which bears US NIH Compound Identifier 47975. European Medicines Agency schedules Anirolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05518MIG. The term ANIROLAC is an International Non-Proprietary Name.

UNSPSC 51385001 Anirolac (Commodity) covers pharmaceutical products and related health supplies procured by state and local health agencies, though recent activity under this code includes naloxone, drug deactivation systems, and broader generic pharmaceuticals and over-the-counter products rather than anirolac specifically. State and local governments buy emergency medical countermeasures, community health supplies, and pharmaceutical inventory through this code via county health departments, state pharmacy benefit programs, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Issuing bodies include county health systems (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) that coordinate procurement on behalf of multiple state and local members. Scope spans both direct procurement of specific quantities for immediate community health use and framework agreements establishing wholesale distribution channels and pricing for pharmaceutical products across participating government entities.

Recent activity concentrates in Florida and Texas, with multistate cooperative purchasing originating in Minnesota but extending to Oregon and other participating jurisdictions. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries with a two-year initial term and one-year renewal option; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capabilities for direct-to-manufacturer pharmacy prescription programs outside traditional pharmacy benefit manager and wholesale channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multistate contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with pricing evaluation weighted 75 percent on competitiveness, two-year initial terms, and optional extensions through June 2028. MMCAP contracts require cGMP and Drug Supply Chain Security Act compliance, $5,000,000 commercial general liability insurance, and 3 percent administrative fees on all purchases.